What we do
Theralytica develops targeted and mechanism-driven cancer therapeutics, informed by tumor and pathogen ecology. Our HOSTILE platform (Host-Oriented Shutdown of Tumor Invasion via Lectin Entry) modulates cancer stemness, senescence, and resistance to chemo and checkpoint inhibitor therapies.
Mechanistic hypotheses grounded in a new understanding of tumor environments.
Clinically validated proof of principle
Theralytica, Inc.
319 N Bernardo Avenue
Mountain View, CA 94043